Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06434155
Other study ID # 17200545
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2022
Est. completion date July 1, 2022

Study information

Verified date May 2024
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The objective of this study is to predict of glaucoma progression. By imaging of the retinal nerve fiber layer RNFL, optic nerve head (ONH) and macular measurements using spectral-domain OCT (SD-OCT) instruments


Description:

Glaucoma is a multifactorial optic neuropathy characterized by structural damage of retinal ganglion cells (RGCs) and their axons that is associated with vision loss and may lead to irreversible blindness. Because glaucomatous damage is irreversible and effective treatment is available to halt further damage, glaucoma management should be optimized with precise micrometer-scale quantifications of ocular structures that improve detection of the disease and its progression. The introduction of OCT technology more than 20 years ago provided in vivo detailed visualization of the optic nerve head (ONH) and retina and enabled the quantitative evaluation of these tructures. Circumpapillary retinal nerve fiber layer (RNFL) thickness is a common OCT measurement that provides comprehensive evaluation of all RGCs in an eye as they converge into the ONH. When measured with spectral-domain OCT, the RNFL has been shown to differentiate between healthy and glaucomatous eyes. The steady evolution of OCT technology has led to imaging with better resolution, higher scanning speeds, and advanced imaging patterns that has improved the reliability of OCT measurements and allowed for detection of minute changes that can improve the sensitivity of progression detection. Assessment of glaucoma progression usually is based on event or trend analysis. Event-based progression determines when a measurement exceeds a pre-established threshold for change from baseline. Trend-based analysis quantifies the rate of a parameter's progression over time.


Recruitment information / eligibility

Status Completed
Enrollment 1584
Est. completion date July 1, 2022
Est. primary completion date July 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - IOP measurements more than 21 mmHg - Open angle on gonioscopy (Grade 3 or 4 on Schaffer grading system for angle width) - Glaucomatous visual field defects consistent with glaucomatous optic disc changes. - Eyes with baseline macular and ONH OCT images and ONH photograps Exclusion Criteria: - Participants with significant retinal disease. - non-glaucomatous optic neuropathy. - anomalous discs - any retinal pathology. - history of cataract or glaucoma surgery will not be exclusion criteria.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Egypt Faculty of Medicine Assiut

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary OCT structural parameters RNFL in (um), ONH in (um), as well as the inner macula thickness (in um) using spectral domain OCT 6 months
See also
  Status Clinical Trial Phase
Completed NCT02754596 - Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution Phase 2
Recruiting NCT00306657 - Normal Tension and Chronic Open Angle Glaucoma and Cerebrospinal Fluid Composition N/A
Enrolling by invitation NCT04381611 - INTEGRAL Study: A Longitudinal Study of Surgeries and Lasers in Glaucoma: Long-term Results and Success Predictors Analysed From a Large-scale Retrospective and Prospective Glaucoma Register